Kornimate/medical-research-clean huggingface dataset:
galileo-hip whole body vibration /conventional physiotherapy /coxarthrosis

Conditions: Coxarthrosis

Summary: osteoarthritis (oa) is the most common degenerative arthropathy. load-bearing joints such as knee and hip are more often affected than spine or hands. the prevalence of gonarthrosis is generally higher than that of coxarthrosis. because no cure for oa exists, the main emphasis of therapy is analgesic treatment through either mobility or medication. non-pharmacologic treatment is the first step, followed by the addition of analgesic medication, and ultimately by surgery. the goal of non-pharmacologic and non-invasive therapy is to improve neuromuscular function, which in turn both prevents formation of and delays progression of oa. a modification of conventional physiotherapy, whole body vibration has been successfully employed for several years. since its introduction, this therapy is in wide use at our facility not only for gonarthrosis, but also coxarthrosis and other diseases leading to muscular imbalance.

this study is a randomized, therapy-controlled trial in a primary care setting at a university hospital. patients presenting to our outpatient clinic with initial symptoms of coxarthrosis will be assessed against inclusion and exclusion criteria. after patient consent, 6 weeks of treatment will ensue. during the six weeks of treatment, patients will receive one of two treatments, conventional physiotherapy or whole-body-vibration exercises of one hour three times a week. follow-up examinations will be performed immediately after treatment and after another 6 and 20 weeks, for a total study duration of 6 months. 20 patients will be included in each therapy group.

Eligibility criteria:
inclusion criteria: * age 30 - 80 years * body weight less than or equal to 160 kg * body-mass-index less than 40 kg/m² * outpatient * legal competence * signed informed consent * uni- or bilateral coxarthrosis according to acr criteria * womac-pain index (visual analogue scale) of 30-70 mm * coxarthrosis stage ii-iii according to kellgren and lawrence exclusion criteria: * participation in parallel interventional studies * bilateral coxarthrosis with womac pain index more than 70 mm * previous surgery during the past 6 months at the index joint * injury of the study joint during the last 6 months * secondary rheumatoid or septic arthrosis or systemic diseases affecting the study joint * activated coxarthrosis with intraarticular effusion * body weight \> 160 kg or body mass index \> 40 kg/m² * analgesic therapy with steroidal drugs * physiotherapy of the lower extremities during the past 6 weeks * existing endoprosthetics in the lower extremities

Keywords: hip, arthrosis
molecular epidemiology of enteroviruses detected at the virology laboratory of brest university hospital during the period 2018-2024: retrospective analysis of an atypical meningitis epidemic in 2024 (brecho9men)

Conditions: Enterovirus Infections; Meningitis, Viral; Meningitis Enterovirus; Echovirus 9

Summary: this study is being done to learn more about enterovirus infections detected in the cerebrospinal fluid of patients at chu de brest. researchers will analyze medical records and laboratory data collected between 2018 and 2024. they will look at how these infections present in patients, and whether a specific virus type, called echo-9, may be associated with different clinical features or represent an emerging variant.


Eligibility criteria:
inclusion criteria: * cerebrospinal fluid (csf) sample positive for enterovirus by rt-pcr between january 1, 2018 and december 31, 2024 , performed at the virology laboratory of chu de brest. * no documented opposition to the use of medical data for research purposes. exclusion criteria: * patients under legal protection (guardianship, curatorship, etc.) * refusal to participate in the study

Keywords: echovirus 9 enterovirus viral meningitis molecular epidemiology phylogenetic analysis rt-pcr retrospective study surveillance france outbreak emerging variant france epidemiology
decreasing upper and shoulder pain after laparoscopic surgery

Conditions: Shoulder Pain; Nausea

Summary: laparoscopic surgery is becoming a major procedure, owing to smaller incisions, shorter hospitalizations, and less post-operative pain as compared with traditional laparotomies. however, there is marked interindividual variability of post-operative shoulder-tip pain following laparoscopic surgery. the incidence of shoulder pain varies from 35% to 80% and ranges from mild to severe. in some cases, it has been reported to last more than 72 hours after surgery. the hypothesis of post-operative shoulder-tip pain is that carbon dioxide induced phrenic nerve irritation causes referred pain to c4. therefore, the investigators should try to do is that if the investigators could reduce carbon dioxide retention in the pelvic cavity. this clinical controlled trial is tried to find out the practical and clinical maneuver to reduce post-operative should-tip pain following laparoscopic surgery.

this clinical controlled trial is tried to find out the practical and clinical maneuver to reduce post-operative upper abdominal and shoulder pain after laparoscopic surgery.

Eligibility criteria:
inclusion criteria: * patients receive benign gynecological laparoscopic surgery * american society of anesthesiologists(asa) physical status of patient classification i-ii. exclusion criteria: * the procedure will be required to conversion to laparotomy * any cardio-vascular diseases

Keywords: shoulder pain upper abdominal pain laparoscopic surgery abdominal fullness
kd019 versus erlotinib in subjects with stage iiib/iv non small cell lung cancer with progression after first- or second-line chemotherapy

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this study involves treatment with kd019 or erlotinib in patients with non-small cell lung cancer (nsclc) who have progressed after first- or second- line chemotherapy. it is hypothesized that kd019 can prolong survival compared with erlotinib.


Eligibility criteria:
for eligibility subjects must have: * failed one or two previous courses of therapy. * have no active brain metastasis. treated non-active brain metastasis are acceptable. * cannot have received an epidermal growth factor receptors inhibitor (tarceva \[erlotinib\] or iressa \[gefitinib\]) in the past. * has demonstrated progressive disease.
differences in efficacy between nasal and oronasal masks in the treatment of osa with cpap

Conditions: Obstructive Sleep Apnea (OSA)

Summary: our group previously conducted a study looking at the performance of three styles of positive airway pressure masks during laboratory treatment studies for obstructive sleep apnea, and we found that patients using a full-mask mask required higher positive airway pressures than patients using nasal or nasal pillows style masks to achieve successful reduction of respiratory events. in the current study we want to randomly assign patients to either nasal or full-face masks and then switch to a different mask (if nasal was originally chosen than the mask will be switched to full-face and vise versa) after 3-weeks of use to see if the number of respiratory events change with the different mask style. we expect the number of respiratory events will increase with the use of full-face masks.


Eligibility criteria:
inclusion criteria: * 18 years or older * previously diagnosed with osa * returning for pap titrations at the center for sleep medicine * cpap and titration naive * must have a apnea/hypopnea index (ahi) of ≥ 16/hr. exclusion criteria: * patients with ≥ 50% central apneas
spira™-a 3d and hct/p dbm vs. medtronic divergent™-l/perimeter™ and recombinant bmp-2

Conditions: Degenerative Disc Disease; Spinal Stenosis; Spondylolisthesis; Scoliosis

Summary: a prospective, randomized, controlled clinical evaluation utilizing the spira™ alif 3-d printed titanium interbody device with dbm vs a medtronic peek alif interbody device with bmp

this is a single blinded randomized 1:1, controlled, prospective clinical study to evaluate fusion status and patient reported outcomes in circumferential lumbar fusion between l2-s1 at a single level with posterior screw fixation (camber spine orthros system) and anterior surgery consisting of one of the treatment groups: subjects treated with the spira™-a interbody device and hctp/p dbm or subjects treated with medtronic divergent-l or perimeter™ peek alif interbody device and rhbmp-2 (6mg per level).

Eligibility criteria:
inclusion criteria: * skeletally mature adults * completed 6 month non-operative or conservative therapy * signed informed consent * back pain with radicular symptoms as evidenced by leg pain * degenerative disc disease involving a single level between l2 and s1 * subject willing to participate in study and follow protocol * subject willing to comply with post-op management program exclusion criteria: * systemic infection such as aids, hiv or active hepatitis * autoimmune disease * significant metabolic disease that might compromise bone growth * history of malignancy * previous surgery for primary tumor, trauma or infection * subject requires 2 or more levels of fusion * previous spinal instrumentation or previous interbody fusion at involved level * spondylolisthesis of grade greater than/equal to 2

Keywords: lumbar spinal fusion
evaluation of ipsilateral tubal patency after conservative medical or surgical treatment.

Conditions: Ectopic Pregnancy

Summary: ectopic pregnancy is an entity in which a fertilized ovum is implanted outside its normal place, is considered a public health problem worldwide and is one of the main causes of maternal mortality in the first trimester. the availability of high sensitivity methods of detection of gonadotrophins and the use of high resolution transvaginal ultrasonography have allowed an earlier diagnosis of the same, enabling less aggressive treatments such as the use of parenteral mtx, with the intention of avoiding mutilating surgical treatment , preserving the tube and eventually improving future fertility expectations. the surgical treatment is of choice, this can be laparoscopically or by laparotomy. in this case, we need to preserve fertility, the most indicated is linear salpingostomy; in spite of the existence other techniques.

the ep constitutes a frequent obstetric emergency in angola and the province of benguela is not exempt from this health problem. every day we see women with this pathology, to which, most of them, they undergo a mutilating surgical treatment (salpingectomy) that impedes their future reproductive capacity. the procreation in the african continent and especially in angola, has great social and family implications that can reach the breaking of marriages and family (broadcast and study of the public television of angola in the program "na lente" no year 2018 taking into account the importance of procreation in the welfare and stability of the marital relationship.main objectiv: to demonstrate the non-inferiority of conservative treatment with mtx in ipsilateral tubal patency after an uncomplicated ectopic pregnancy compared with surgical treatment with linear salpingostomy in the hospital general, angola

Eligibility criteria:
inclusion criteria: patient presenting with ectopic pregnancy, associated with quantitative titers of βhcg ≥ 100 mui / ml, without intrauterine gestational sac. patient presenting uncomplicated ectopic pregnancy with an adnexal mass diameter ≤4 cm diagnosed by abdominal and / or transvaginal ultrasonography. absence of heartbeat. no toxicity to mtx. normal laboratory tests (blood count, coagulogram, liver and kidney function). hemodynamic stability. exclusion criteria: * complicated ectopic pregnancy. * ectopic pregnancy is out of the tuba on ultrasound * patients with immunosuppression. * allergy to mtx. * patients with active respiratory disease, blood dyspasia, peptic ulcer, renal insufficiency and hepatic insufficiency. * do not accept to participate in the study.

Keywords: uncomplicated ectopic pregnancy methotrexate
effects of action observation and motor imagery on orofacial sensorimotor variables

Conditions: Pain

Summary: the main objective of the present study was to evaluate the effects of different dosages of action observation (ao) and motor imagery (mi) combined with an orofacial exercise program on pain pressure thresholds, lingual endurance and perceived exertion in asymptomatic subjects.


Eligibility criteria:
inclusion criteria: 1. healthy individuals with no pain 2. aged between 18 and 65 years 3. subjects with correct masticatory function and labial and lingual mobility exclusion criteria: 1. individuals who presented systemic, cardiorespiratory, central nervous system or rheumatic diseases, or those who presented any musculoskeletal or craniocervical pathology 2. underage individuals 3. individuals with orofacial pain or temporomandibular disorders at the time of the study 4. subjects' complaint of toothache or tenderness to percussion.

Keywords: motor imagery action observation
development of therapeutic intervention for sleep in alzheimer/caregiver dyads

Conditions: Alzheimer's Disease

Summary: this non-intervention qualitative study will use focus groups to assess the feasibility and acceptability of a proposed intervention for a future study. the focus group will discuss a potential biobehavioral family self-management intervention designed to improve sleep in persons with alzheimer's disease (pad) and their caregivers (cg).

approximately 16 caregivers of home-based pad/cg dyads (person with alzheimer's disease/caregiver dyads) will be recruited from the community. a series of two audiotaped focus groups will be conducted with these caregiver participants. the first focus group will explore perspectives on what constitutes a feasible and acceptable intervention to improve their sleep and associated symptoms. the second focus group will consist of follow up and confirmation of findings from the first focus group. the intervention will be developed and refined based upon focus group findings.

Eligibility criteria:
inclusion criteria: 1. screen positive on the promis sleep disturbance and associated symptoms measures 2. be a caregiver within a pad/cg dyad 3. speak/understand english 4. agree to be audiotaped during focus group participation 5. be at least 18 years of age exclusion: 1. they negative on the promis sleep disturbance and associated symptoms measures, 2. are not a caregiver within a pad/cg dyad, 3. do not speak/understand english, 4. refuse to take part in audiotaping of the focus groups, 5. are not at least 18 years of age.
five-year immune persistence study of inactivated enterovirus type 71 (ev71) vaccine

Conditions: Hand, Foot and Mouth Disease

Summary: the purpose of this study is to evaluate the 5-year immune persistence of inactivated enterovirus type 71 (ev71) vaccine manufactured by sinovac (beijing) biotech co., ltd.

the phase iii, efficacy trial of inactivated vaccine (vero cell) against ev71 has completed on march 2013 in china,and a follow up study for phase iii clinical trial has completed on march 2014. on the basis of phase iii, this study is the phase iv, open-labelled research, in order to evaluate the 5-year immune persistence of ev71 vaccine.

Eligibility criteria:
inclusion criteria: in the prior phase iii clinical trial, 10077 subjects in three counties (ganyu, sheyang and taixing ) were enrolled ( experimental group: 5044; control group: 5043 ), with 1293 of them in immunogenicity subgroup (experimental group: 648; control group: 645). in sheyang county, 3351 subjects were enrolled (experimental group: 1676 ; control group :1675) , with 435 of them in immunogenicity subgroup (experimental group: 418 ; control group :418). the subjects in sheyang immunogenicity subgroup with the following conditions were included in this study: * guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study * received at least one injection of ev71 vaccine or the placebo in the phase iii clinical trial * finished the blood sampling 64 months after the vaccination exclusion criteria: * received extra ev71 vaccination after the phase iii clinical trial * refused to join the study

Keywords: inactivated enterovirus type 71 (ev71) vaccine 5-year immune persistence
the baby care study

Conditions: Sleep; Parenting; Eating Behavior; Obesity

Summary: the objective of this study is to provide pilot data on the feasibility and effectiveness of a web-based social networking intervention designed to promote sleep early in infancy and to explore the potential for this approach to promote healthy feeding routines, eating behaviors, and weight outcomes in subsequent larger-scale intervention research. first-time parents will be recruited (n=66) and randomized to an 8-week web-based social networking sleep intervention or general baby care control group with interventions beginning at infant age 8 weeks. parents will complete online surveys, with research questions including: 1) whether the sleep intervention leads to longer nighttime and total sleep duration and decreased night waking among infants and 2) longer infant sleep bouts and improved parent sleep duration, stress, parenting efficacy, and parenting satisfaction. we will also examine infants' routines, feeding and eating behaviors, and emotion regulation to inform the application of this approach for childhood obesity prevention. the pilot research will provide insights into intervention feasibility, effects on infant sleep, and potential impacts on feeding and eating outcomes, informing our next steps.


Eligibility criteria:
inclusion criteria: * english-speaking, first-time parents/legal guardians \>18 years of a young infant who is \< 6 weeks at the time of recruitment (or pregnant first-time parents expecting an infant soon). we will not include any parents who report that they do not have access to or an interest in using a private group on social media and/or online surveys. exclusion criteria: * we will exclude families not meeting age criteria, as well as any parents who report that they do not have access to or an interest in using a private group on social media and/or online surveys. we will also exclude parents of infants who are born premature (prior to 37 weeks gestational age) and parents of multiples (twins, triplets, etc.).
the state of sexual development in children with inherited epidermolysis bullosa

Conditions: Dermatologic Disease; Epidermolysis Bullosa; Epidermolysis Bullosa Simplex; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Kindler Syndrome; Puberty Disorders; Hormone Disturbance

Summary: the aim of the study is to determine the state of sexual development in patients with inherited epidermolysis bullosa; the study is planned to include boys and girls aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex, junctional epidermolysis bullosa, kindler syndrome.

determination of sexual development in children with various types of inherited epidermolysis bullosa using clinical, laboratory and instrumental methods for diagnosing the condition. phenotyping of patients with inherited epidermolysis bullosa, taking into account their physical and sexual development, indicators of self-attitude and socialization. development of algorithms for individual care for patients with inherited epidermolysis bullosa, including an assessment of the psychological state at different age stages (primary school and adolescence), the volume and form of psychological and pedagogical assistance in complex rehabilitation.

Eligibility criteria:
inclusion criteria: 1. male and female patients from 8 to 18 years of age with an established diagnosis of epidermolysis bullosa simplex, junctional epidermolysis bullosa, dystrophic epidermolysis bullosa, kindler syndrome. exclusion criteria: 1. hypergonadotropic hypogonadism; 2. previous treatment with sex steroids or gonadotropins; 3. the presence of endocrine diseases (hypothyroidism, hypercorticism, hyperprolactinemia, diabetes mellitus); 4. the presence of chronic somatic diseases that are not complications of inherited epidermolysis bullosa (bronchopulmonary diseases, cardiovascular diseases, diseases of the urinary system, diseases of the gastrointestinal tract).

Keywords: inherited epidermolisys bullosa epidermolisys bullosa epidermolisys bullosa simplex epidermolisys bullosa junctional epidermolisys bullosa dystrophic kindler syndrome puberty sexual development epidermolysis bullosa congenital epidermolysis bullosa
trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in covid-19 patients without signs of severity

Conditions: Budesonide; Olfaction Disorders; SARS-CoV-2; Anosmia

Summary: the initial symptoms described in the first cases of covid-19 were mainly fever and respiratory signs. recently, there has been an increase in cases of hyposmia without associated nasal obstruction or rhinorrhea. although we do not yet know the long-term consequences of covid-19 on olfaction, there is evidence in the literature demonstrating that post-viral hyposmias are an important source of long-term olfactory disorders, impacting quality of life. usually, the treatment of viral hyposmias is based on local and/or general corticosteroid treatment combined with saline nasal irrigation at the onset of signs. because of the possible development of severe forms of the sars-cov-2 infection, the french society of otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal irrigation. however, as the virus is present in the nasal fossae on average for 20 days, persistent hyposmia at 30 days would probably result from an inflammatory or neurological damage to the nasal slits or olfactory bulb. local treatment with corticosteroids could then be instituted from 30 days after the onset of symptoms of covid-19 without risk of dissemination. in persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation. however, this drug does not have marketing authorisation in france for this indication.

this is a multicenter randomized trial to evaluate the efficacy of local budesonide (nasal irrigation) in the management of persistent hyposmia in covid-19 patients.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age; * patient with a suspected sars-cov-2 infection in a epidemic context, whether or not confirmed by pcr, or contact close to a pcr-confirmed case, typical chest ct scan (unsystematized frosted glass areas predominantly sub-pleural, and at a later stage of alveolar condensation with no excavations neither nodules nor masses) or positive serology ; * patient with isolated acute hyposmia persisting at d30. of the onset of signs of ca-mrsa-cov-2 infection; * absence of pcr-confirmed sars-cov-2 portage at the time of inclusion exclusion criteria: * known hypersensitivity to budesonide or to any of the excipients of the medicine; * hemostasis disorder, or epistaxis; * oromo-oral-nasal and ophthalmic herpes virus infection; * long-term corticosteroid treatment; * treatment with potent cyp3a4 inhibitors (e.g., cyp3a4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and hiv proteases) ; * forms of cov-2-sars with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms; * hyposmia persisting for more than 90 days after onset of symptoms; * other causes of hyposmia revealed on interrogation or an mri;